$ESLA 8-K SEC Filings

Filed On	Filing
08 Sep 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule On September 1, 2026, Estrella Immunopharma, Inc. (the “Company”) received a written notification (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the market val...
21 Aug 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
30 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
13 Jan 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
06 Jan 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
04 Dec 2025	8-K: Other Events
06 Nov 2025	8-K: Other Events
29 Sep 2025	8-K: Other Events
26 Sep 2025	8-K: Departure/Election of Directors or Officers; Compensation
07 Aug 2025	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
05 Jun 2025	8-K: Other Events
03 Jun 2025	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
29 May 2025	8-K: Other Events
02 May 2025	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
21 Feb 2025	8-K: Other Events
20 Feb 2025	8-K: Other Events
16 Dec 2024	8-K: Other Events
06 Dec 2024	8-K: Entry into a Material Definitive Agreement
26 Nov 2024	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
25 Nov 2024	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Comments